Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT-FGF14: Fampridine in SCA27B (FGF14 GAA expansion)
2024-520413-53-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in spinocerebellar ataxia type 27b (SCA27B) comparing Fampridine with Placebo (2 arms). Primary endpoint: Proportion of patients with ≥0.5-point improvement in FARS-Functional Staging at week 12 vs baseline. Planned start Oct 2025; status: authorised.
02
Drugs
dalfampridine
03
Conditions
spinocerebellar ataxia type 27b (SCA27B)
Beyond the preview
Go deeper on 2024-520413-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520413-53-00.